Publish in this journal
Journal Information
Vol. 72. Issue 6.
Pages 516 (June 2019)
Vol. 72. Issue 6.
Pages 516 (June 2019)
Letter to the Editor
Full text access
Vaccination in Patients With Heart Disease. How Long Should We Wait? Response
Vacunación del paciente cardiópata. ¿Hasta cuándo esperar? Respuesta
Nikolaos P.E. Kadogloua,
Corresponding author

Corresponding author:
, John Parissisb, Petar Seferovicc, Gerasimos Filippatosb,d
a Centre for Statistics in Medicine - Botnar Research Centre, University of Oxford, Oxford, United Kingdom
b Heart Failure Unit, Attikon University Hospital, National and Kapodistrian University of Athens, Greece
c Belgrade University School of Medicine, Department of Cardiology, Clinical Center of Serbia, Belgrade, Serbia
d School of Medicine, University of Cyprus, Nicosia, Cyprus
Related content
Rev Esp Cardiol. 2019;72:51510.1016/j.rec.2018.08.023
Vivencio Barrios, Carlos Escobar
This item has received
Article information
Full Text
Download PDF
Full Text
To the Editor,

We read with interest the letter by Barrios and Escobar responding to our editorial, titled “Vaccination in Heart Failure: An Approach to Improve Outcomes”.1 We would like to clarify that our editorial focused exclusively on the impact of anti-influenza and/or antipneumococcal vaccination in patients with already established heart failure (HF) rather than those without a history of HF. It is rational to assume that, if respiratory infections are an important cause of HF hospitalization, preventing such infections would prevent HF patients from frequent readmissions and worsening disease. In agreement with this assumption, large-scale, observational studies or population-based registries have reported a reduction in hospitalization rate of vaccinated HF patients.2,3 On the other hand, limited data indicate that anti-influenza and antipneumococcal vaccination may not further improve clinical outcomes after discharge of HF patients4 or their annual efficacy may be limited only during the “flu seasons”.5 Notably, international guidelines have recommended anti-influenza and antipneumococcal vaccination in HF population based on either level of evidence IIb or on self-care skills or education plans.1 Thus, there are data favoring immunization against influenza and pneumococcal viruses as a cost-effective, preventive measure in the HF population. However, those data are not strong enough to allow firm conclusions. We need more evidence, derived from studies properly designed for HF populations, balancing the risk-benefit ratio and not being extrapolated from general community or “heart disease” patients. Worldwide, the vaccination rate remains low and only evidence-based data will encourage the endorsement of international vaccination programs in HF therapeutic strategies.

Conflicts of interest

J. Parissis received honoraria for lectures from Pfizer.

N.P.E. Kadoglou, J. Parissis, P. Seferovic, G. Filippatos.
Vaccination in Heart Failure: An Approach to Improve Outcomes.
Rev Esp Cardiol., 71 (2018), pp. 697-699
O. Vardeny, B. Claggett, J.A. Udell, et al.
Influenza vaccination in patients with chronic heart failure: The PARADIGM-HF Trial.
JACC Heart Fail., 4 (2016), pp. 152-158
Y.A. Fang, C.I. Chen, J.C. Liu, L.C. Sung.
Influenza vaccination reduces hospitalization for heart failure in elderly patients with chronic kidney disease: a population-based cohort study.
Acta Cardiol Sin., 32 (2016), pp. 290-298
A.S. Bhatt, L. Liang, A.D. DeVore, et al.
Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure.
JACC Heart Fail., 6 (2018), pp. 844-855
F. Alla, F. Zannad, G. Filippatos.
Epidemiology of acute heart failure syndromes.
Heart Fail Rev., 12 (2007), pp. 91-95
Copyright © 2019. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?